M. Daudon and P. Jungers, Drug-Induced Renal Calculi, Drugs, vol.79, issue.3, p.245, 2004.
DOI : 10.2165/00003495-200464030-00003

D. K. Dhodi, S. B. Bhagat, D. Pathak, and S. B. Patel, Drug-induced nephrotoxicity, International Journal of Basic & Clinical Pharmacology, vol.3, issue.4, p.591, 2014.
DOI : 10.5455/2319-2003.ijbcp20140826

A. Wong-beringer, J. Joo, E. Tse, and P. Beringer, Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy, International Journal of Antimicrobial Agents, vol.37, issue.2, p.95, 2011.
DOI : 10.1016/j.ijantimicag.2010.10.013

N. Pabla and Z. Dong, Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies, Kidney International, vol.73, issue.9, p.994, 2008.
DOI : 10.1038/sj.ki.5002786

M. Kass, A. E. Kolker, and M. Gordon, Acetazolamide and Urolithiasis, Ophthalmology, vol.88, issue.3, p.261, 1981.
DOI : 10.1016/S0161-6420(81)35041-6

A. Dessombz, D. Bazin, P. Dumas, C. Sandt, J. Sule-suso et al., Shedding Light on the Chemical Diversity of Ectopic Calcifications in Kidney Tissues: Diagnostic and Research Aspects, PLoS ONE, vol.32, issue.11, p.28007, 2011.
DOI : 10.1371/journal.pone.0028007.t001

Q. D. Nguyen and M. Daudon, Infrared and Raman Spectra of Calculi, 1997.

C. S. Crumpacker, Mechanism of action of foscarnet against viral polymerases, The American Journal of Medicine, vol.92, issue.2, p.3, 1992.
DOI : 10.1016/0002-9343(92)90329-A

G. Deray, F. Martinez, C. Katlama, B. Levaltier, H. Beaufils et al., Foscarnet Nephrotoxicity: Mechanism, Incidence and Prevention, American Journal of Nephrology, vol.9, issue.4, p.316, 1989.
DOI : 10.1159/000167987

H. Beaufils, G. Deray, C. Katlama, E. Dohin, D. Henin et al., Foscarnet and crystals in glomerular capillary lumens, The Lancet, vol.336, issue.8717, p.755, 1990.
DOI : 10.1016/0140-6736(90)92253-E

M. Daudon, L. Estepa, J. Viard, D. Joly, and P. Jungers, Urinary stones in HIV-1-positive patients treated with indinavir, The Lancet, vol.349, issue.9061, p.1294, 1997.
DOI : 10.1016/S0140-6736(05)62506-8

G. J. Wirth, J. Teuscher, J. D. Graf, and C. , Efavirenz-induced urolithiasis, Urological Research, vol.64, issue.4, pp.288-289, 2006.
DOI : 10.1007/s00240-006-0052-6

H. Izzedine, M. A. Valantin, M. Daudon, H. Ait-mohand, F. Caby et al., Efavirenz urolithiasis, AIDS, vol.21, issue.14, p.1992, 2007.
DOI : 10.1097/QAD.0b013e3282ef792f

A. Jafari, H. Khalili, S. Dashti-khavidaki, and E. , Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention, European Journal of Clinical Pharmacology, vol.12, issue.4, p.1029, 2014.
DOI : 10.1007/s00228-014-1712-z

M. Zaidan, F. Lescure, I. Brocheriou, S. Dettwiler, J. Guiard-schmid et al., Tubulointerstitial Nephropathies in HIV-Infected Patients over the Past 15 Years: A Clinico-Pathological Study, Clinical Journal of the American Society of Nephrology, vol.8, issue.6, p.930, 2013.
DOI : 10.2215/CJN.10051012
URL : https://hal.archives-ouvertes.fr/inserm-00919109

U. C. Brewster and M. A. Perazella, Acute interstitial nephritis associated with atazanavir, a new protease inhibitor, American Journal of Kidney Diseases, vol.44, issue.5, p.81, 2004.
DOI : 10.1016/S0272-6386(04)01093-5

H. Izzedine, M. B. M-'rad, A. Bardier, M. Daudon, and D. Salmon, Atazanavir crystal nephropathy, AIDS, vol.21, issue.17, p.2357, 2007.
DOI : 10.1097/QAD.0b013e3282f17503

H. R. Chang and P. M. Pella, Atazanavir Urolithiasis, New England Journal of Medicine, vol.355, issue.20, p.2158, 2006.
DOI : 10.1056/NEJMc061892

K. M. Chan-tack, M. M. Truffa, K. A. Struble, and D. B. Birnkrant, Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration??s Adverse Event Reporting System, AIDS, vol.21, issue.9, p.1215, 2007.
DOI : 10.1097/QAD.0b013e32813aee35